Myriad Genetics IncMYGN
What Myriad Genetics Inc does.
Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.
Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission. We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services.
Our long-term growth str ategy is buil t on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine. Our strategy also leverages invest ments in science and innovation, technology-enabled operations, an enhanced customer experience, strong commercial execution, and scalable operations. Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum (CCC) market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $557.1M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Net income | -$223.6M | -$27.2M | -$112.0M | -$263.3M | -$127.3M | -$365.9M |
| Free cash flow | — | $600,000 | -$151.6M | — | — | — |
More on MYGN.
- Myriad Genetics Inc summary
- Myriad Genetics Inc financial statements
- Myriad Genetics Inc key metrics
- Myriad Genetics Inc health scores and style box
- Myriad Genetics Inc earnings
- Myriad Genetics Inc dividends
- Myriad Genetics Inc valuation
- Myriad Genetics Inc ownership and insiders
- Myriad Genetics Inc peers
Figures from Myriad Genetics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.